Los Angeles Capital Management
GYRE icon

Los Angeles Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Los Angeles Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-122
Closed -$456K – 1238
2014
Q1 		$456K Buy
+122
New +$452K 0.01% 908

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Los Angeles Capital Management's GYRE Position: Q2 2014 in Review

Los Angeles Capital Management sold out of Gyre Therapeutics (GYRE) in Q2 2014, closing a stake of 122 shares — an estimated $456K sold.

Los Angeles Capital Management first reported a position in GYRE in Q1 2014 and held it in 1 quarter. The position peaked at $456K in Q1 2014. 63 funds tracked by Wall St. Rank hold GYRE as of Q2 2014.

  • Los Angeles Capital Management reported no remaining Gyre Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Los Angeles Capital Management sold 122 Gyre Therapeutics shares in Q2 2014, an estimated $456K.
  • Los Angeles Capital Management first reported a position in Gyre Therapeutics in Q1 2014 and held it in 1 quarter.
  • Los Angeles Capital Management's Gyre Therapeutics position peaked at $456K in Q1 2014.
  • 63 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2014.

Based on Los Angeles Capital Management's 13F filing for Q2 2014, filed 12 Aug 2014.